HESTER BIOSCIENCES LTD
Financial trend (100/100) does the heavy lifting; valuation (50/100) is the drag.
Fair valueOur blended model reads HESTER BIOSCIENCES LTD as a Strong Buy at 76/100. At ₹2,477.7 it trades above our blended DCF and relative-multiples fair value of ₹2,332.73, about 6% downside to that estimate — we read it as fairly valued. On 34.2x trailing earnings it sits roughly in line with the Healthcare median of about 37.6x. It's trading right at its 52-week high of ₹2,534. Financial health scores 55/100. It clears 7 of 11 investability checks, with durability 72, valuation 59 and momentum 99 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹1,866.18.
1-year price
EOD · 2026-07-3152-week range
-2.22% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Strong Buy76Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Pass: ROE above 15%: 16.6%
- Fail: Low debt (D/E < 0.5): 0.53x
- Pass: Positive free cash flow
- Pass: Revenue growth > 10%: 40%
- Pass: Earnings growing: 969%
- Pass: Net margin ≥ 10%: 16.7%
- Fail: Current ratio > 1.5: 1.37
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- No data: Altman Z in safe zone
- No data: Piotroski ≥ 7
Shareholding
- Promoter68.8%
- Institutions0.3%
- Public & other30.9%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Healthy profit margin (16.7%).
- Trading near its 52-week high.
Opportunities
- Earnings growing (969% YoY).
- Revenue growing (40% YoY).
About HESTER BIOSCIENCES LTD
Hester Biosciences manufactures and sells veterinary vaccines and animal health products in India and international markets through two segments: Poultry Healthcare and Animal Healthcare. Its poultry vaccine portfolio addresses diseases including newcastle disease, infectious bronchitis, infectious bursal disease, fowl pox, marek's disease, infectious coryza, fowl cholera, inclusion body hepatitis, fowl typhoid, and avian encephalomyelitis.
HESTER BIOSCIENCES LTD — frequently asked questions
Is HESTER BIOSCIENCES LTD a buy, hold or sell?
StocksWizard currently rates HESTER BIOSCIENCES LTD (HESTERBIO) a Strong Buy, based on a blended score of 76/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is HESTER BIOSCIENCES LTD's fair value?
Our blended DCF and relative-valuation model estimates HESTER BIOSCIENCES LTD's fair value at about ₹2,332.73, versus a current price of ₹2,477.7 — roughly 6% downside. On that basis the stock looks fairly valued.
Is HESTER BIOSCIENCES LTD financially healthy?
HESTER BIOSCIENCES LTD scores 55/100 on our financial-health model.
How has HESTER BIOSCIENCES LTD's share price performed?
HESTER BIOSCIENCES LTD is up 52% over three months, and last traded at ₹2,477.7. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.